Morningside Group Ltd. purchased $3.75M worth of shares in Kezar Life Sciences, Inc. in June 2018

Jul 08, 2018
Insider Transactions
Background Information
Morningside Group is an active, long-term manager which invests in a range of sectors including telecom and Internet, machinery manufacturing, high-tech, media, telecommunications, life sciences and education sectors. They invets in companies in North America, Europe and Asia Pacific, with a particular focus on China.The firm seeks to create value in their investee companies, partnering with managementto develop strategy, build the necessary management infrastructure, access domestic and international growth opportunities and achieve optimal investment exit through capital market operations.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.